VASTox provides grant to support Duchenne Muscular Dystrophy patient registry
VASTox plc has provided a grant to the UK muscular dystrophy charity, Parent Project UK (PPUK), to support the development and management of its Duchenne muscular dystrophy (DMD) patient registry.
The DMD Registry aims to register every person in the UK with DMD and Becker muscular dystrophy, including detailed clinical and genetic data, in a secure, legally protected database that has been endorsed by senior clinicians, health professionals and researchers. It will be used by these groups to help accelerate the development and delivery of new treatments for Duchenne and Becker muscular dystrophies by providing an easier route to clinical trials in the UK.
Ultimately, this registry will be used by VASTox, and other organisations engaged in the development of therapies for muscular dystrophies, to support Phase II and Phase III clinical trials in the UK. The grant will be used by PPUK to recruit a full-time project manager and to help raise awareness of the registry among clinicians, patients and their families.
The resource will also provide information for families of DMD patients, including the latest developments in research for treatments for DMD, which will enable them to make better decisions about their future medical care needs.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
